Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PGK1 | P00558 | 1/20 | 0.31 |
| ▸ | PGK2 | P07205 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | FDPS | P14324 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11411465 | 0.81 | LMNA (0.50) | LMNACYP2C19KDM4ETDP1TSHR | |
| SCHEMBL8160310 | 0.77 | LMNA (0.46) | LMNACYP2C19KDM4ETDP1TSHR | |
| SCHEMBL11111802 | 0.77 | CYP2C19 (0.42) | LMNACYP2C19KDM4ETDP1TSHR | |
| Trichlorfon SCHEMBL6266785 | 0.73 | LMNA (1.00) | LMNACYP2C19 | |
| Trichlorfon SCHEMBL116996 | 0.73 | LMNA (1.00) | LMNACYP2C19 | |
| SCHEMBL8154047 | 0.73 | LMNA (0.38) | LMNACYP2C19KDM4ETDP1TSHR | |
| Trichlorfon SCHEMBL15972 | 0.73 | LMNA (1.00) | LMNACYP2C19 | |
| SCHEMBL3860656 | 0.71 | LMNA (0.47) | LMNACYP2C19KDM4ETDP1TSHR | |
| SCHEMBL7173221 | 0.71 | LMNA (0.41) | LMNACYP2C19KDM4ETDP1TSHR | |
| SCHEMBL28790839 | 0.69 | KDM4E (0.37) | LMNACYP2C19KDM4ETDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3618819-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | Exciva GmbH (DE) | 2020-03-11 | — | — | EP | claimed |
| US-20200069674-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | Exciva GmbH (DE) | 2020-03-05 | — | — | US | claimed |
| WO-2018204713-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | EXCIVA UG (HAFTUNGSBESCHRÄNKT) (DE) | 2018-11-08 | — | — | WO | claimed |
| US-20090185867-A1 | MARINE ANTI-FOULANT SYSTEM AND METHODS FOR USING SAME | ASSET INTEGRITY MANAGEMENT SOLUTIONS, L.L.C., D/B/A AIMS INTERNATIONAL | 2009-07-23 | — | — | US | claimed |
| US-6966142-B1 | Insect trap | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 2005-11-22 | — | — | US | claimed |
| US-20030144255-A1 | Compositions for prevention and treatment of dementia | BAIN ALLEN I (CA) | 2003-07-31 | — | — | US | claimed |
| WO-2001066096-A2 | COMPOSITIONS FOR PREVENTION AND TREATMENT OF DEMENTIA | IMMUNE NETWORK LTD. (CA) | 2001-09-13 | — | — | WO | claimed |
| US-5922404-A | Process for producing dimethyl (2,2,2-trichloro-1-hydroxyethyl)-phosphonate and granular formulations thereof | BAYER CORPORATION (US) | 1999-07-13 | — | — | US | claimed |
| EP-0824504-B1 | IMPROVED DESTRUCTION OF ELECTRON AFFINIC CONTAMINANTS DURING WATER TREATMENT USING FREE RADICAL PROCESSES | RES CORP TECHNOLOGIES INC (US) | 1999-07-07 | — | — | EP | claimed |
| EP-0824504-A1 | IMPROVED DESTRUCTION OF ELECTRON AFFINIC CONTAMINANTS DURING WATER TREATMENT USING FREE RADICAL PROCESSES | Research Corporation Technologies, Inc (US) | 1998-02-25 | — | — | EP | claimed |
| EP-0799159-A1 | DECHLORINATION OF TCE WITH PALLADIZED IRON | Research Corporation Technologies, Inc (US) | 1997-10-08 | — | — | EP | claimed |
| EP-0449975-B1 | NON-TIN-BASED, LOW TOXICITY ANTI-FOULING AGENTS | BATTELLE MEMORIAL INSTITUTE (US) | 1997-04-23 | — | — | EP | claimed |
| WO-1996035642-A1 | IMPROVED DESTRUCTION OF ELECTRON AFFINIC CONTAMINANTS DURING WATER TREATMENT USING FREE RADICAL PROCESSES | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1996-11-14 | — | — | WO | claimed |
| WO-1996020137-A1 | DECHLORINATION OF TCE WITH PALLADIZED IRON | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1996-07-04 | — | — | WO | claimed |
| US-5441743-A | In thermoplastic or thermosetting binder | BATTELLE MEMORIAL INSTITUTE (US) | 1995-08-15 | — | — | US | claimed |
| EP-0431361-B1 | Use of stabilizers for agrochemical compositions | BAYER AGROCHEM KK (JP) | 1994-02-23 | — | — | EP | claimed |
| WO-1990006975-A1 | NON-TIN-BASED, LOW TOXICITY ANTI-FOULING AGENTS | BATTELLE MEMORIAL INSTITUTE (US) | 1990-06-28 | — | — | WO | claimed |
| US-3937825-A | PHOSPHONATE, IMIDAZO(2,1-B)THIAZOLE HYDROCHLORIDE | AMERICAN CYANAMID COMPANY (US) | 1976-02-10 | — | — | US | claimed |
| US-20240074434-A1 | COMPOSITION INCLUDING EFFERVESCENT AGENTS, BIOSTIMULANT, NUTRIENT, AND PESTICIDE | ROBBINS JEFFREY HANSON (US) | 2024-03-07 | — | — | US | disclosed |
| US-3937825-A | PHOSPHONATE, IMIDAZO(2,1-B)THIAZOLE HYDROCHLORIDE | AMERICAN CYANAMID COMPANY (US) | 1976-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200069674-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | HTR2A, HTR2C, CYP3A43 | LMNA 1421/4885CYP2C19 6/4885KDM4E 3464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.